Gonadotrophin Releasing Hormone Agonist Addition for Luteal Support in In-vitro Fertilization and Embryo Transfer Cycles

Phase 1

• Conditions: GnRHa;LPS
• Interventions: Drug: Gonadotrophin releasing hormone agonist(GnRHa)

• Registration Number: NCT02908438
• Lead Sponsor: Northwest Women's and Children's Hospital, Xi'an, Shaanxi

Brief Summary

The study was designed to investigate the effect of luteal-phase administration of gonadotrophin releasing hormone agonist(GnRHa) on pregnancy outcomes in in-vitro fertilization-embryo transfer.

Detailed Description

Not available

Study Timeline

• Status Verified: 2016-09
• Study Start: 2016-09
• Study First Submitted: 2016-09-12
• Study First Submitted QC: 2016-09-20
• Last Update Submitted: 2016-09-20
• Study First Posted: 2016-09-21
• Last Update Posted: 2016-09-21
• Primary Completion: 2017-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 400

Inclusion Criteria

1. Age < 37 years;
2. One or more high quality embryos have been got in IVF/ICSI treatment;
3. To transfer at lest 2 fresh embryos;
4. Uterine endometrial thickness ≥ 7mm;
5. Patients have signed informed consents.

Exclusion Criteria

1. ≥3 IVF/ICSI/FET cycles and no pregnancy;
2. Polycystic ovary syndrome(PCOS);
3. uterine malformation;
4. endometriosis
5. patients with a history of recurrent pregnancy loss.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
GnRHa group	Gonadotrophin releasing hormone agonist(GnRHa)	Intervention: additional GnRHa for routine LPS GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.

Primary Outcome Measures

Name	Time	Method
pregnancy rate	up to 12 months